Rett syndrome

Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25

Retrieved on: 
金曜日, 4月 19, 2024
FDA, Congress, Heart, Rett syndrome, Conference, Research, Duchenne muscular dystrophy, ChromeOS, Patient, EMA, Erythropoietic protoporphyria, Drug development, Fragile X syndrome, Clinical trial, TGA, Pharmaceutical industry

Avance Clinical CEO, Yvonne Lungershausen said that Avance Clinical is dedicated to advancing research and ensuring faster access to therapies that can make a significant difference in patients' lives.

Key Points: 
  • Avance Clinical CEO, Yvonne Lungershausen said that Avance Clinical is dedicated to advancing research and ensuring faster access to therapies that can make a significant difference in patients' lives.
  • "Avance Clinical is focussed on accelerating drug development for its biotech clients, from preclinical stages through to Phase III," she said.
  • Visit Booth #730 to discuss your upcoming clinical trial, and find out more about the Avance Clinical Advantage, supporting biotechs globally in their clinical development programs.
  • Visit Booth #730 to discuss your drug development program at the World Orphan Drug Congress in Boston, April 23- 25

AVXL Stockholders: Additional Lawsuit Filed Against Anavex Life Sciences Corporation; Contact Robbins LLP Regarding the May 13, 2024 Lead Plaintiff Deadline

Retrieved on: 
木曜日, 5月 9, 2024
CNS, Central nervous system, Complaint, News, LLP, Rett syndrome, Person, Patient, Excellence, SAN, Rett, Pharmaceutical industry

For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Anavex sponsored the “Excellence” Phase II/Phase III study to investigate blarcamesine as a treatment for pediatric Rett syndrome patients.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.
  • Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 13, 2024.

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
木曜日, 5月 9, 2024
FDA, News, Central nervous system disease, Complaint, Rett syndrome, Neurodevelopmental disorder, Research, CNS, Avatar, Patient, Court, Central nervous system, Excellence, Person, Fraud, Pharmaceutical industry

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) and certain of its officers.

Key Points: 
  • NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) and certain of its officers.
  • Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Investors in Anavex Life Sciences Corporation Should Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights – AVXL

Retrieved on: 
木曜日, 5月 9, 2024
MCI, News, Radar, NEXT, Rett syndrome, Patient, Clinical trial, Fraud, Security (finance)

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).

Key Points: 
  • NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).
  • Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

ANAVEX ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corp. and Encourages Investors to Contact the Firm

Retrieved on: 
木曜日, 5月 9, 2024
MCI, News, Radar, Rett syndrome, P.C, District court, Patient, Court, Clinical trial, Telephone, Person

Investors have until May 13, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 13, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.
  • Biotech analysts commented that “the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results.”
    Following this news, AVXL’s stock price fell by $3.26 per share, or approximately 35%.

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Fast Track, Research, Rett syndrome, Trial of the century, Partnership, Doctor of Philosophy, Conference call, CNS, Procedure, Frontotemporal dementia, EDGAR, Food, Orphan drug, European Medicines Agency, Brain, RWE, MECP2, Drug development, RNA-Seq, Conference, Publication, Pharmacokinetics, U.S. FDA, Marketing authorisation, DSM-IV codes, Patent, Real, RNA, Human, Therapy, Treatment, EMA, Alzheimer's disease, Central nervous system, Clinical trial, Medicine, Marketing, ADAS, Centralisation, Pharmacology, European, Patient, Expanded access, Caregiver, Webcast, Interim, Bank statement, Pharmaceutical industry

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended March 31, 2024.

Key Points: 
  • Parkinson’s disease: Initiation of ANAVEX®2-73 imaging-focused trial and Phase 2b/3 6 month trial is expected in the second half of 2024.
  • General and administrative expenses for the quarter of $2.8 million compared to $2.9 million for the comparable quarter of fiscal 2023.
  • Research and development expenses for the quarter of $9.7 million compared to $11.3 million for the comparable quarter of fiscal 2023.
  • The financial information for the fiscal quarter ended March 31, 2024, should be read in conjunction with the Company’s condensed consolidated interim financial statements, which will appear on EDGAR, www.sec.gov and will be available on the Anavex website at www.anavex.com .

Shape Therapeutics RNAfix® Editing Platform Achieves >90% Editing in Mouse and Non-Human Primate Brain

Retrieved on: 
水曜日, 5月 8, 2024
Brain, Transcriptome, AI, Rett syndrome, RNA, MD, Doctor of Philosophy, Cell, AAV, CNS, DNA, Patient, Gene, Society, Central nervous system, NHP, Annual general meeting, ADAR, Vaccine

SEATTLE, May 08, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, today presented data at the 27th American Society for Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore, MD showcasing the high therapeutic potential of its RNAfix platform in for the treatment of central nervous system (CNS) disorders.

Key Points: 
  • Potential therapeutic applications of RNAfix will be highlighted in Rett syndrome, Parkinson’s disease, and Alzheimer’s disease, showcasing a diversity of therapeutic mechanisms enabled by nucleotide-level precision RNA editing.
  • A superior safety profile will also be presented, with no significant off-target editing across the entire transcriptome.
  • The data presented at ASGCT highlight levels of editing in the CNS unparalleled by any other editing technology, unlocking vast therapeutic opportunities.
  • Importantly, the RNAfix platform leaves genomic DNA intact and does not require the delivery of foreign proteins with immunogenicity risks.

Anavex Life Sciences Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights – AVXL

Retrieved on: 
火曜日, 5月 7, 2024
MCI, LLP, News, CLASS, Radar, NEXT, Rett syndrome, Patient, Court, Clinical trial, Telephone, COST

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Anavex Life Sciences investors who were adversely affected by alleged securities fraud between February 1, 2022 and January 1, 2024.
  • Follow the link below to get more information and be contacted by a member of our team:
    AVXL investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Stride Autism Centers Opens New Facility in Oak Park to Improve Autism Services in Illinois

Retrieved on: 
月曜日, 5月 6, 2024
NCSP, ABA, OAK, Spectrum, LMFT, Rett syndrome, Doctor of Philosophy, Research, Applied behavior analysis, BCBA, Child, LCP, Ageing, Nursing

OAK PARK, Ill., May 06, 2024 (GLOBE NEWSWIRE) -- Stride Autism Centers ("Stride"), renowned for its mission-driven, evidence-based therapy for children with autism, announces the opening of its innovative new center in Oak Park, Illinois.

Key Points: 
  • OAK PARK, Ill., May 06, 2024 (GLOBE NEWSWIRE) -- Stride Autism Centers ("Stride"), renowned for its mission-driven, evidence-based therapy for children with autism, announces the opening of its innovative new center in Oak Park, Illinois.
  • This strategic expansion is a significant step in Stride's mission to increase access to specialized autism services for children throughout the Midwest.
  • Located at 6400 W North Ave, Chicago, IL 60707, the Oak Park center is set to provide Stride’s celebrated full-day Applied Behavior Analysis (ABA) therapy programs.
  • The Oak Park center upholds our high standards and adapts our proven methods to meet the specific needs of each child."

Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview

Retrieved on: 
水曜日, 5月 8, 2024
Mental Health, Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Prader–Willi syndrome, Safety, PIN, Poster, Research and development, Pimavanserin, Rett syndrome, Somatic symptom disorder, Patient, Observational study, Caregiver, ACAD, Journal, Growth, Pharmaceutical industry

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024.
  • Net product sales of NUPLAZID were $129.9 million for the first quarter of 2024, an increase of 10% as compared to $118.5 million for the first quarter of 2023.
  • Acadia is reiterating all of its 2024 guidance provided on February 27, 2024.
  • Acadia will host a conference call to discuss the first quarter 2024 results today, Wednesday, May 8, 2024 at 1:30 p.m. PT/4:30 p.m.